北京科拓恒通生物技术股份有限公司 2025 年第三季度报告 证券代码：300858 证券简称：科拓生物 公告编号：2025-043 北京科拓恒通生物技术股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： □是 否 1 北京科拓恒通生物技术股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 104,043,568.35 | 28.98% | 267,389,193.46 | 22.25% | | 归属于上市公司股东 | 35,026,934.69 | 26.56% | 76,231,997.73 | 7.08% | | 的净利润（元） | | | | | | 归属于上市公司股东 的扣除非经常性损益 | 31, ...

Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]

Core Insights - On October 12, no A-share listed companies disclosed any increase in shareholding, while six companies reported share reductions [1] Group 1: Companies Reporting Share Reductions - Lian Ce Technology's controlling shareholder's concerted actors plan to reduce their holdings by no more than 2.98% [2] - Baolidi's shareholder holding over 5% (Yunnan Trust) plans to reduce holdings by no more than 1 million shares [2] - Zhongrong Electric's controlling shareholder's concerted actors intend to reduce their holdings by no more than 0.999% [2] - Ketaobiological's specific shareholder Zhang Liebing plans to reduce holdings by no more than 1.8976% [2] - Yirui Biological's controlling shareholder and its concerted actors plan to reduce holdings by no more than 3% [2] - Shanghai Hohong's major shareholder Xinggang Rongchuang plans to reduce holdings by no more than 1% [2]

科拓生物（300858）(300858.SZ)发布公告，持有股4.1764%的特定股东张列兵计划在次减持公告披露之 日起3个交易日后的3个月内(即2025年10月16日至2026年1月15日)以集中竞价、大宗交易的方式拟减持 公司股份数量不超过500万股，即不超过公司股份总数的1.8976%。 ...

智通财经APP讯，科拓生物(300858.SZ)发布公告，持有股4.1764%的特定股东张列兵计划在次减持公告 披露之日起3个交易日后的3个月内(即2025年10月16日至2026年1月15日)以集中竞价、大宗交易的方式 拟减持公司股份数量不超过500万股，即不超过公司股份总数的1.8976%。 ...

每经头条（nbdtoutiao）——万亿美元"世纪豪赌"！英伟达、OpenAI等巨头集体出手！循环融资靠谱 吗？专家：AI泡沫规模已是2008年全球房地产泡沫的4倍 每经AI快讯，科拓生物10月12日晚间发布公告称，持有北京科拓恒通生物技术股份有限公司股份约 1100万股（占公司总股本比例约为4.18%）的特定股东张列兵计划在本次减持公告披露之日起3个交易 日后的3个月内（即2025年10月16日至2026年1月15日）以集中竞价、大宗交易的方式拟减持公司股份数 量不超过500万股，即不超过公司股份总数的1.8976%。 （记者 王晓波） ...

南财智讯10月12日电，科拓生物公告，特定股东张列兵计划在未来3个月内（2025年10月16日至2026年1 月15日）通过集中竞价和大宗交易的方式减持不超过500万股，占公司总股本的1.8976%。张列兵目前 持有公司1100.4613万股，占总股本的4.1764%。减持原因为个人资金需求。张列兵在公司首次公开发行 股票并上市时做出了一系列股份锁定和减持承诺，截至目前均已履行。公司提醒投资者关注减持计划的 实施进展和市场风险。 ...

证券代码：300858 证券简称：科拓生物 公告编号：2025-041 北京科拓恒通生物技术股份有限公司 关于特定股东减持股份预披露公告 公司股东张列兵保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有北京科拓恒通生物技术股份有限公司（以下简称"公司"）股份11,004,613 股（占公司总股本比例4.1764%）的特定股东张列兵计划在本次减持公告披露之 日起3个交易日后的3个月内（即2025年10月16日至2026年1月15日）以集中竞价、 大宗交易的方式拟减持公司股份数量不超过5,000,000股，即不超过公司股份总数 的1.8976%。 公司于近日收到特定股东张列兵出具的《关于股份减持计划的告知函》，现 将相关情况公告如下： 一、股东的基本情况 | 股东名称 | 持股数量（股） | 占公司总股本比例 | | --- | --- | --- | | 张列兵 | 11,004,613 | 4.1764% | 二、本次减持计划的主要内容 1、减持原因：个人资金需求。 3、减持数量：拟计划减持股 ...

证券日报网讯9月10日晚间，科拓生物（300858）发布公告称，选举马杰先生为公司第三届董事会职工 代表董事。 ...

一、关于董事辞任的情况 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于近日收到非独 立董事马杰先生提交的书面辞职报告，因公司治理结构及内部工作调整，马杰先 生申请辞去公司第三届董事会董事职务，辞任后将继续担任公司生产运营总监以 及在公司全资子公司北京大地海腾工贸有限公司担任总经理、执行董事职务。马 杰先生的辞任不会导致公司董事会成员低于法定最低人数，其辞任自公司收到辞 职报告之日生效。 证券代码：300858 证券简称：科拓生物 公告编号：2025-040 北京科拓恒通生物技术股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 附件： 马杰先生简历 特此公告。 北京科拓恒通生物技术股份有限公司 董事会 2025 年 9 月 10 日 1、马杰先生辞职报告； 2、职工代表大会会议决议。 二、关于选举职工代表董事的情况 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、规范性文件以及《公司章程》 的有关规定，公司于 2025 年 9 月 10 日 ...